News
Enzalutamide Active in Low-, Intermediate-Risk Prostate Cancer
Significant reduction seen in risk of prostate cancer progression for enzalutamide plus AS versus active surveillance alone
Significant reduction seen in risk of prostate cancer progression for enzalutamide plus AS versus active surveillance alone